This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swift, P. A Articles by MacGregor, G. A Search for Related Content PubMed PubMed Citation Articles by Swift, P. A Articles by MacGregor, G. A Social Bookmarking                         What's this?

Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers

Blood Pressure Unit, St. George's Hospital Medical School, London

Graham A MacGregor

Blood Pressure Unit, St. George's Hospital Medical School, London, g.macgregor{at}sghms.ac.uk

Key Words: Type 2 diabetes • hypertension • diabetic nephropathy • angiotensin II receptor blockers • renoprotection

References

• Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.Diabeticoligia 1998;41:745-59.
• Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetics. Ann Int Med 1993;118:577-81.[Abstract/Free Full Text]
• Dinneen SF, Gerstein HC The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic review of the literature. Arch Int Med 1997; 157(13):1413-8.[Abstract/Free Full Text]
• Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.[Free Full Text]
• Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens1993;11:319-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.NEnglJMed 1993;329:1456-62.[Abstract/Free Full Text]
• Viberti G., Mongensen CE, Groop LC, Pauls JF for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin dependent diabetes and microalbuminuria. J Am Med Assoc 1994;271:275-9.[Abstract/Free Full Text]
• Björck S., Mulek H., Johnsen SA, Nordén G.,Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:330-43.[Free Full Text]
• Heart Out comes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tatti P., Pahor M., Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDMM. Diabetes Care 1998;21:597-603.[Abstract]
• Estacio RO, Jeffers BW, Hiatt RA, Biggerstaff SL, Gifford N., Schrier RW The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.[Abstract/Free Full Text]
• Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tuomillehto J., Rastenyte D.,Thisj L., Staessen J. Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertensionin Europe treated with nitrendipine-based antihypertensive therapy (Syst-Eur Trial) (Abstract) Diabetes Care 1998;47:A57.
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-20.[Abstract/Free Full Text]
• Parving H-H., Lehnert, H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.NEnglJMed 2001;345:870-8.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Clarke WR et al. for the Collaborative Study Group. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, de Zeeuw D. et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.NEnglJMed 2001;345:861-9.[Abstract/Free Full Text]
• Rodby RA, Rohde RD, Clarke WR et al. for the Collaborative Study Group. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000;15:487-97.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, de Zeeuw D. et al. for the RENAAL Study Investigators. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS 2000;1(4):328-35.[Medline] [Order article via Infotrieve]
• Amos AF, McCarthy DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997;14:S7-S85.[CrossRef][Web of Science]
• USRDS: Annual Data Report. Chapter 5. Patient mortality and survival. 1995;91-108, www.usrds.org
• The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ruggeneti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., Scolari F., Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Aggodoa YA, Appel L., Bakris GL et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis. A Randomised Controlled Trial. JAMA 2001;285:2719-28.[Abstract/Free Full Text]
• Anderson S.,Tarnow L., Rossing P., Hansen BV, Parving HH Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.[Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 3, 170-173 (2001)
DOI: 10.3317/jraas.2001.023


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swift, P. A Articles by MacGregor, G. A Search for Related Content PubMed PubMed Citation Articles by Swift, P. A Articles by MacGregor, G. A Social Bookmarking                         What's this?